MCL1 Inhibitor

ANJ810

MCL1 is a member of the Bcl-2 family, normally acting as a “brake” on the apoptosis pathway. In many human cancers, the Mcl-1 gene is highly amplified, shifting the balance between pro- and anti-apoptotic signals and promoting cancer cell survival and tumor formation.

Restoring the “Brake” on Cancer

All cells have intrinsic survival and renewal mechanisms - but cancer finds ways to tilt the balance and allow tumors to grow unchecked.

A Catalytic Discovery

Compared to drug discovery efforts targeting other Bcl-2 family members, progress versus MCL1 has proven more difficult. The team at Anji solved a key problem for MCL1 – developing a robust platform for structure-based design – that enabled the discovery of ANJ810. This molecule selectively blocks MCL1 function and induces rapid and specific killing of cancer cells in preclinical models when administered as a single agent or in combination with other targeted therapy. Now, it’s full steam ahead to bring this powerful therapeutic agent to patients.

For partnerships, investment opportunities, or to learn more about our work, contact us.